Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Cozzi Lepri

Showing results (121-130 of 227) with videos related to

Pageof 23
Sort By:
Journal of the International AIDS Society|November 15, 2014
Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational settingNicola Gianotti, Alessandro Cozzi-Lepri, Andrea Antinori, et al.
Plos One|March 4, 2014
Timing of antiretroviral therapy initiation after a first AIDS-defining event: temporal changes in clinical attitudes in the ICONA cohortAntonella Cingolani, Alessandro Cozzi-Lepri, Adriana Ammassari, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 11, 2018
Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort StudySebastiano Leone, Milensu Shanyinde, Alessandro Cozzi Lepri, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|August 14, 2025
Burden of advanced HIV disease among antiretroviral therapy-experienced persons with HIV in Italy over the past 20 yearsAnnalisa Mondi, Alessandro Cozzi-Lepri, Valentina Mazzotta, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|April 13, 2024
Risk of SARS-CoV-2 infection in patients with hematologic diseases receiving tixagevimab/cilgavimab as pre-exposure prophylaxis in most recent Omicron sublineages eraAlessandra Vergori, Alessandro Cozzi Lepri, Marta Chiuchiarelli, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|June 21, 2023
Neutralizing activity and T-cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIVAlessandra Vergori, Giulia Matusali, Alessandro Cozzi Lepri, et al.
Journal of Medical Virology|April 16, 2024
Poor durability of the neutralizing response against XBB sublineages after a bivalent mRNA COVID-19 booster dose in persons with HIVGiulia Matusali, Alessandra Vergori, Eleonora Cimini, et al.
Plos One|February 14, 2017
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patientsNicola Gianotti, Alessandro Cozzi-Lepri, Andrea Antinori, et al.
Journal of Viral Hepatitis|February 18, 2021
The impact of DAA-mediated HCV eradication on CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation CohortAlessandra Bandera, Patrizia Lorenzini, Lucia Taramasso, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 6, 2024
Heavily treatment-experienced persons living with HIV currently in care in Italy: characteristics, risk factors, and therapeutic options-the ICONA Foundation cohort studySergio Lo Caputo, Mariacristina Poliseno, Alessandro Tavelli, et al.
Pageof 23

Showing results (121-130 of 227) with videos related to

Sort By:
Pageof 23
Journal of the International AIDS Society|November 15, 2014
Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational settingNicola Gianotti, Alessandro Cozzi-Lepri, Andrea Antinori, et al.
Plos One|March 4, 2014
Timing of antiretroviral therapy initiation after a first AIDS-defining event: temporal changes in clinical attitudes in the ICONA cohortAntonella Cingolani, Alessandro Cozzi-Lepri, Adriana Ammassari, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 11, 2018
Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort StudySebastiano Leone, Milensu Shanyinde, Alessandro Cozzi Lepri, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|August 14, 2025
Burden of advanced HIV disease among antiretroviral therapy-experienced persons with HIV in Italy over the past 20 yearsAnnalisa Mondi, Alessandro Cozzi-Lepri, Valentina Mazzotta, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|April 13, 2024
Risk of SARS-CoV-2 infection in patients with hematologic diseases receiving tixagevimab/cilgavimab as pre-exposure prophylaxis in most recent Omicron sublineages eraAlessandra Vergori, Alessandro Cozzi Lepri, Marta Chiuchiarelli, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|June 21, 2023
Neutralizing activity and T-cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIVAlessandra Vergori, Giulia Matusali, Alessandro Cozzi Lepri, et al.
Journal of Medical Virology|April 16, 2024
Poor durability of the neutralizing response against XBB sublineages after a bivalent mRNA COVID-19 booster dose in persons with HIVGiulia Matusali, Alessandra Vergori, Eleonora Cimini, et al.
Plos One|February 14, 2017
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patientsNicola Gianotti, Alessandro Cozzi-Lepri, Andrea Antinori, et al.
Journal of Viral Hepatitis|February 18, 2021
The impact of DAA-mediated HCV eradication on CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation CohortAlessandra Bandera, Patrizia Lorenzini, Lucia Taramasso, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 6, 2024
Heavily treatment-experienced persons living with HIV currently in care in Italy: characteristics, risk factors, and therapeutic options-the ICONA Foundation cohort studySergio Lo Caputo, Mariacristina Poliseno, Alessandro Tavelli, et al.
Pageof 23